Author:
Kegler Alexandra,Drewitz Laura,Arndt Claudia,Daglar Cansu,Rodrigues Loureiro Liliana,Mitwasi Nicola,Neuber Christin,González Soto Karla Elizabeth,Bartsch Tabea,Baraban Larysa,Ziehr Holger,Heine Markus,Nieter Annabel,Moreira-Soto Andres,Kühne Arne,Drexler Jan Felix,Seliger Barbara,Laube Markus,Máthé Domokos,Pályi Bernadett,Hajdrik Polett,Forgách László,Kis Zoltán,Szigeti Krisztián,Bergmann Ralf,Feldmann Anja,Bachmann Michael
Abstract
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to millions of infections and deaths worldwide. As this virus evolves rapidly, there is a high need for treatment options that can win the race against new emerging variants of concern. Here, we describe a novel immunotherapeutic drug based on the SARS-CoV-2 entry receptor ACE2 and provide experimental evidence that it cannot only be used for (i) neutralization of SARS-CoV-2 in vitro and in SARS-CoV-2-infected animal models but also for (ii) clearance of virus-infected cells. For the latter purpose, we equipped the ACE2 decoy with an epitope tag. Thereby, we converted it to an adapter molecule, which we successfully applied in the modular platforms UniMAB and UniCAR for retargeting of either unmodified or universal chimeric antigen receptor-modified immune effector cells. Our results pave the way for a clinical application of this novel ACE2 decoy, which will clearly improve COVID-19 treatment.
Subject
Immunology,Immunology and Allergy